Greystone Financial Group LLC Has $10.98 Million Position in Danaher Co. (NYSE:DHR)

Greystone Financial Group LLC grew its position in shares of Danaher Co. (NYSE:DHR) by 39.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 47,810 shares of the conglomerate’s stock after purchasing an additional 13,443 shares during the quarter. Danaher makes up 1.9% of Greystone Financial Group LLC’s holdings, making the stock its 20th biggest holding. Greystone Financial Group LLC’s holdings in Danaher were worth $10,975,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Kentucky Retirement Systems Insurance Trust Fund grew its holdings in Danaher by 11.6% during the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate’s stock worth $4,874,000 after acquiring an additional 2,202 shares during the last quarter. Fort Pitt Capital Group LLC lifted its holdings in shares of Danaher by 3.2% during the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock worth $66,194,000 after purchasing an additional 7,421 shares during the period. ORG Partners LLC grew its stake in shares of Danaher by 1,212.8% in the fourth quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after purchasing an additional 2,559 shares during the last quarter. Harvest Portfolios Group Inc. increased its holdings in Danaher by 1.2% in the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock valued at $56,233,000 after purchasing an additional 2,465 shares during the period. Finally, Generate Investment Management Ltd acquired a new stake in Danaher in the fourth quarter valued at $8,044,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Price Performance

Shares of DHR opened at $209.86 on Friday. The business’s fifty day moving average is $226.71 and its 200 day moving average is $247.11. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The stock has a market cap of $151.58 billion, a P/E ratio of 39.75, a P/E/G ratio of 2.61 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period last year, the business earned $2.09 EPS. Sell-side analysts anticipate that Danaher Co. will post 7.67 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.61%. This is an increase from Danaher’s previous quarterly dividend of $0.27. Danaher’s payout ratio is 20.45%.

Insiders Place Their Bets

In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of analyst reports. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research report on Thursday, October 31st. Wells Fargo & Company reduced their target price on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Barclays lowered their price target on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Guggenheim started coverage on shares of Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target on the stock. Finally, Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research report on Friday, December 13th. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.